PharmaDrug Joint Venture Receives Approval For Phase 1 Clinical Trial

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study in Australia. The trial aims to assess a reformulated version of oral cepharanthine, referred to as PD-001, as a treatment for cancer and medical countermeasures.

The phase 1 study is set to take place in Australia, following an approval by the Australian Human Research Ethics Committee for an in-human clinical study. Once completed in Australia, the research will be used to support a submission to the US Food and Drug Administration for phase 2 and phase 3 clinical trials in the US.

“We are extremely excited to have achieved this significant milestone for PD-001. This is the product of several years of research and development with the aim of unlocking the therapeutic potential of our patented enhanced bioavailability cepharanthine to potentially treat cancers, infectious diseases and viral pandemics,” commented PharmaDrug CEO Robert Steen.

READ: PharmaDrug Enters Letter Of Intent With Licensed Dealer For Pharma Grade Cocaine

PD-001 is an enteric-coated orally bioavailable formulation of cepharanthine. The patented drug is intended to treat a variety of acute and chronic diseases. The original version of cepharanthine has been in use for over seven decades in Japan, with the drug showing multiple pharmacological properties such as anti-oxidative, anti-inflammatory, immuno-regulatory, anti-viral, anti-cancer, and anti-parasitic effects.

The original version of the drug however has suffered from low oral bioavailability, which has limited it from realizing its full potential. PD-001, Sairiyo’s patented version of the drug, has been shown in trials with rodents to markedly improve oral bioavailability, meaning the body can more easily absorb the drug. 

The approval for a phase one study follows the company submitting an application back in May 2024.

PharmaDrug last traded at $0.01 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Khiron Life Sciences Looks To Acquire PharmaDrug’s German Subsidiary For $2.0 Million

Khiron Life Sciences Corp. (TSXV: KHRN) announced today the plan to acquire Pharmadrug GmbH, a...

Tuesday, May 31, 2022, 10:34:00 AM

PharmaDrug: A Path To Safe Supply

In this interview, David Kideckel, CEO of PharmaDrug (CSE: PHRX), discusses the company's groundbreaking biosynthetic...
Wednesday, March 13, 2024, 01:30:00 PM

PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

PharmaDrug Inc (CSE: PHRX) has established a strategic plan to push forward with its intent...
Monday, May 13, 2024, 08:55:00 AM

Aura Health Completes Name Change to Pharmadrug Inc

Aura Health (CSE: BUZZ) announced this morning that it has completed its name change to...

Monday, October 21, 2019, 09:28:36 AM

Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method

PharmaDrug's (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine....
Wednesday, March 13, 2024, 08:45:11 AM